{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:31:03Z","timestamp":1760315463272,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Care Nursing Clinics of North America"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ccell.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T11:15:07Z","timestamp":1385032507000},"page":"459-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chronic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"given":"Edythe M.","family":"(Lyn) Greenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Probst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2013.09.003_bib1","unstructured":"National Cancer Institute. SEER stat facts: leukemia. 2009. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/leuks.html. Accessed March 21, 2013."},{"key":"10.1016\/j.ccell.2013.09.003_bib2","series-title":"MD Anderson manual of medical oncology","first-page":"1","author":"Kantarjian","year":"2006"},{"key":"10.1016\/j.ccell.2013.09.003_bib3","unstructured":"National Cancer Institute. SEER stat facts: chronic myeloid leukemia. 2009. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. Accessed January 31, 2013."},{"key":"10.1016\/j.ccell.2013.09.003_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","article-title":"Important therapeutic targets in chronic myelogenous leukemia","volume":"13","author":"Kantarjian","year":"2007","journal-title":"Clin Cancer Res"},{"year":"2011","series-title":"Chronic myeloid leukemia","author":"Cortes","key":"10.1016\/j.ccell.2013.09.003_bib5"},{"key":"10.1016\/j.ccell.2013.09.003_bib6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2013.09.003_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1021\/mp300405n","article-title":"Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation","volume":"10","author":"Woessner","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ccell.2013.09.003_bib8","article-title":"24 Months update of the TOPS study","volume":"114","author":"Baccarani","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ccell.2013.09.003_bib9","unstructured":"National Cancer Institute. NCI guidelines for investigators: adverse event reporting requirements. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/aeguidelines.pdf. Accessed February 29, 2013."},{"key":"10.1016\/j.ccell.2013.09.003_bib10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2013.09.003_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3\u00a0randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ccell.2013.09.003_bib12","article-title":"Clinical significance of complete cytogenetic response (CCyR) and major molecular response (MMR) achieved with different treatment modalities used as frontline therapy in chronic myeloid leukemia (CML) chronic phase","volume":"118","author":"Alattar","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ccell.2013.09.003_bib13","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccell.2013.09.003_bib14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccell.2013.09.003_bib15","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA Trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccell.2013.09.003_bib16","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccell.2013.09.003_bib17","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia","volume":"112","author":"Jabbour","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2013.09.003_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2013.09.003_bib19","series-title":"Williams hematology","first-page":"1431","article-title":"Chronic lymphocytic leukemia and related diseases","author":"Kipps","year":"2010"},{"key":"10.1016\/j.ccell.2013.09.003_bib20","series-title":"MD Anderson manual of medical oncology","first-page":"33","article-title":"Chronic lymphocytic leukemia and associated disorders","author":"Garg","year":"2011"},{"key":"10.1016\/j.ccell.2013.09.003_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/107327481201900104","article-title":"Front-line therapy for chronic lymphocytic leukemia","volume":"19","author":"Desai","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.ccell.2013.09.003_bib22","first-page":"379","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2001","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ccell.2013.09.003_bib23","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Halleck","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2013.09.003_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/107327481201900103","article-title":"Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia","volume":"19","author":"Sagatys","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.ccell.2013.09.003_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/107327481201900102","article-title":"Clinical aspects of monoclonal B-cell lymphocytosis","volume":"19","author":"Mowery","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.ccell.2013.09.003_bib26","first-page":"692","article-title":"Adverse prognostic features in chronic lymphocytic leukemia","volume":"258","author":"Mougalian","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.ccell.2013.09.003_bib27","series-title":"Williams hematology","first-page":"777","article-title":"Hemolytic anemia resulting from immune injury","author":"Packman","year":"2010"},{"key":"10.1016\/j.ccell.2013.09.003_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","volume":"2008","author":"Dearden","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ccell.2013.09.003_bib29","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccell.2013.09.003_bib30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrclinonc.2010.101","article-title":"Chemoimmunotherapy of chronic lymphocytic leukemia","volume":"7","author":"Tam","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ccell.2013.09.003_bib31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine cyclophosphamide, and rituximab regimen as initial therapy of chronic leukemia","volume":"9","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2013.09.003_bib32","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2013.09.003_bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/107327481201900106","article-title":"Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia","volume":"19","author":"Carballido","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.ccell.2013.09.003_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/107327481201900107","article-title":"Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens","volume":"19","author":"Karfan-Dabaja","year":"2012","journal-title":"Cancer Control"}],"container-title":["Critical Care Nursing Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899588513000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899588513000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:27:07Z","timestamp":1760268427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899588513000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0899588513000737"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2013.09.003","relation":{},"ISSN":["0899-5885"],"issn-type":[{"type":"print","value":"0899-5885"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Critical Care Nursing Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2013.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}